Published in Am J Hypertens on July 01, 2002
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev (2010) 1.50
Cellular ADMA: regulation and action. Pharmacol Res (2009) 1.42
Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol (2009) 1.20
Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant (2008) 1.15
Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol (2008) 1.13
Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension (2012) 1.04
Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol (2007) 0.95
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol (2012) 0.91
The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol (2011) 0.87
Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study. Cardiovasc Diabetol (2013) 0.82
Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol (2013) 0.81
The antihypertensive effect of arginine. Int J Angiol (2008) 0.81
Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2011) 0.80
n-3 polyunsaturated fatty acids supplementation decreases asymmetric dimethyl arginine and arachidonate accumulation in aging spontaneously hypertensive rats. Eur J Nutr (2004) 0.79
The levels of asymmetric dimethylarginine in patients with isolated coronary artery ectasia. Ann Saudi Med (2010) 0.77
Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm (2010) 0.76
Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes. Eur J Clin Pharmacol (2009) 0.75
Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats. Front Physiol (2016) 0.75
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study. Int J Mol Sci (2016) 0.75
Renin-Angiotensin system inhibitors reduce serum asymmetric dimethylarginine levels and oxidative stress in normotensive patients with chronic kidney disease. Nephron Extra (2014) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med (2007) 2.97
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Practice and perception--a nationwide survey of therapy habits in sepsis. Crit Care Med (2008) 2.43
Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension (2003) 2.34
Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant (2007) 2.25
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol (2008) 1.92
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 1.89
Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol (2011) 1.85
Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med (2003) 1.83
Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol (2010) 1.77
Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol (2010) 1.70
Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant (2007) 1.66
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2007) 1.65
AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens (2002) 1.63
Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension (2012) 1.54
Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. J Hypertens (2011) 1.53
Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol (2013) 1.52
Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens (2011) 1.51
Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension (2006) 1.51
23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. Hypertension (2013) 1.51
Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling. Chem Biol (2012) 1.50
Remodeling of retinal small arteries in hypertension. Am J Hypertens (2011) 1.50
Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens (2012) 1.49
Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res (2011) 1.49
Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics (2007) 1.47
Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders. Pflugers Arch (2003) 1.47
Ca2+ but not H2O2 modulates GRE-element activation by the human mineralocorticoid receptor in HEK cells. Mol Cell Endocrinol (2006) 1.46
The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant (2004) 1.46
Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens (2003) 1.45
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis (2008) 1.44
New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. J Hypertens (2011) 1.44
Elevation of sympathetic activity by eprosartan in young male subjects. Am J Hypertens (2003) 1.42
Fourier analysis of the envelope of the ophthalmic artery blood flow velocity: age- and blood pressure related impact. Hypertension (2007) 1.41
Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens (2002) 1.41
Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int (2002) 1.41
Folic acid treatment normalizes NOS-dependence of vascular tone in the metabolic syndrome. Obesity (Silver Spring) (2010) 1.40
Haemoglobin and vascular function in the human retinal vascular bed. J Hypertens (2013) 1.39
Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. Nephrol Dial Transplant (2002) 1.39
Effect of aliskiren on vascular remodelling in small retinal circulation. J Hypertens (2015) 1.39
Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients. J Hypertens (2010) 1.39
High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. J Hypertens (2007) 1.37
Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. J Clin Hypertens (Greenwich) (2014) 1.37
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens (2012) 1.37
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens (2007) 1.36
Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension (2007) 1.33
(23)Na magnetic resonance imaging of tissue sodium. Hypertension (2011) 1.29
(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension (2008) 1.27
Beyond salt: lifestyle modifications and blood pressure. Eur Heart J (2011) 1.24
Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int (2004) 1.24
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J (2005) 1.22
Salt and hypertension: is salt dietary reduction worth the effort? Am J Med (2012) 1.22
Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. J Hypertens (2009) 1.13
Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke (2004) 1.12
Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension (2004) 1.11
Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens (2008) 1.10
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens (2010) 1.09
Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens (2005) 1.08
Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. J Hypertens (2008) 1.08
Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrol Dial Transplant (2009) 1.07
Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med (2005) 1.07
Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol (2007) 1.07
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 1.06